Senescent fibroblast‑driven mucin glycosylation reshapes gut microbiota, causing the late‑life decline in Firmicutes/Bacteroidetes ratio

Dr. Lena Rocha· Mar 26, 2026

Mechanism: Senescent fibroblasts alter mucin glycosylation, reducing Firmicutes binding and increasing Bacteroidetes, which lowers butyrate and fuels inflammation. Readout: Readout: MMP-9 inhibition restores mucin galactose, increases Firmicutes abundance, raises butyrate production by 80%, and reduces inflammation by 60%.

Hypothesis

Aging colonic fibroblasts develop a senescence-associated secretory phenotype (SASP) that alters mucin O‑glycosylation, reducing the binding affinity of mucin for butyrate‑producing Firmicutes (e.g., Roseburia, Faecalibacterium) while preserving or enhancing adhesion for mucin‑degrading Bacteroidetes. This shift in the mucosal niche explains the biphasic F/B ratio: early‑life increases reflect expansion of Firmicutes as the mucosal surface matures; after ~70 years, fibroblast‑driven mucin remodeling creates a permissive environment for Bacteroidetes, lowering the ratio despite continued loss of butyrate genes[1].

Mechanistic Rationale

Senescent fibroblasts secrete MMP‑9 and TGF‑β, which activate colonic epithelial glycosyltransferases (e.g., C1GALT1) leading to increased sialylation and fucosylation of MUC2[2].
Altered glycan motifs diminish lectin‑like interactions with Firmicutes surface adhesins that preferentially bind terminal galactose/N‑acetylglucosamine residues, whereas Bacteroidetes utilize polysaccharide‑utilization loci (PULs) that recognize sialylated/fucosylated glycans[3].
Consequently, butyrate‑producing Firmicutes lose mucosal residence, drop luminal concentrations, and their metabolic output (butyrate) falls, triggering colonocyte energy stress, AMPK activation, and barrier leak as previously described[4].
The resulting LPS influx fuels inflammaging, which further reinforces fibroblast senescence via NF‑κB signaling, establishing a positive feedback loop[5].

Testable Predictions

Prediction 1: Colonic fibroblast isolates from donors >70 years will show higher SA‑β‑gal activity and secrete elevated MMP‑9/TGF‑β compared with <60 year donors; conditioned media will increase MUC2 sialylation/fucosylation in HT‑29 monolayers (measured by lectin blot)[6].
Prediction 2: Mucin from old‑donor fibroblasts will exhibit reduced binding to recombinant Roseburia intestinalis adhesin (measured by surface plasmon resonance) but unchanged or increased binding to Bacteroides thetaiotaomicron outer‑membrane lipoprotein[6].
Prediction 3: Oral administration of a MMP‑9 inhibitor (e.g., SB‑3CT) to aged mice will restore mucin galactose exposure, increase fecal Firmicutes abundance, raise luminal butyrate, and improve colonic tight‑junction protein (Claudin‑1) levels relative to vehicle controls[7].
Prediction 4: Transplant of fibroblasts from young donors into the colonic submucosa of aged germ‑free mice will prevent the age‑associated F/B ratio reversal and mitigate inflammaging markers (serum IL‑6, hippocampal H3K9ac)[8].

Falsifiability

If fibroblast‑conditioned media does not alter mucin glycosylation, or if mucin glycan changes fail to correlate with differential bacterial adhesion in vitro, the core mechanism is refuted. Likewise, if MMP‑9 inhibition does not rescue Firmicutes abundance or butyrate levels in aged mice, the hypothesis loses support.

Broader Impact

Linking stromal senescence to mucosal glycan ecology offers a unifying explanation for the paradoxical F/B ratio reversal and suggests stromal‑targeted therapies (senolytics, glycosidase adjuncts) to sustain butyrate production and inhibit inflammaging in extreme old age.

Hypothesis

Mechanistic Rationale

Senescent fibroblasts secrete MMP‑9 and TGF‑β, which activate colonic epithelial glycosyltransferases (e.g., C1GALT1) leading to increased sialylation and fucosylation of MUC2[2].

Altered glycan motifs diminish lectin‑like interactions with Firmicutes surface adhesins that preferentially bind terminal galactose/N‑acetylglucosamine residues, whereas Bacteroidetes utilize polysaccharide‑utilization loci (PULs) that recognize sialylated/fucosylated glycans[3].

Consequently, butyrate‑producing Firmicutes lose mucosal residence, drop luminal concentrations, and their metabolic output (butyrate) falls, triggering colonocyte energy stress, AMPK activation, and barrier leak as previously described[4].

The resulting LPS influx fuels inflammaging, which further reinforces fibroblast senescence via NF‑κB signaling, establishing a positive feedback loop[5].

Testable Predictions

Prediction 1: Colonic fibroblast isolates from donors >70 years will show higher SA‑β‑gal activity and secrete elevated MMP‑9/TGF‑β compared with <60 year donors; conditioned media will increase MUC2 sialylation/fucosylation in HT‑29 monolayers (measured by lectin blot)[6].

Prediction 2: Mucin from old‑donor fibroblasts will exhibit reduced binding to recombinant Roseburia intestinalis adhesin (measured by surface plasmon resonance) but unchanged or increased binding to Bacteroides thetaiotaomicron outer‑membrane lipoprotein[6].

Prediction 3: Oral administration of a MMP‑9 inhibitor (e.g., SB‑3CT) to aged mice will restore mucin galactose exposure, increase fecal Firmicutes abundance, raise luminal butyrate, and improve colonic tight‑junction protein (Claudin‑1) levels relative to vehicle controls[7].

Prediction 4: Transplant of fibroblasts from young donors into the colonic submucosa of aged germ‑free mice will prevent the age‑associated F/B ratio reversal and mitigate inflammaging markers (serum IL‑6, hippocampal H3K9ac)[8].

Falsifiability